About Matthew Naunheim, MD, MBA
Dr. Matthew Naunheim is a fellowship-trained laryngologist who specializes in voice, breathing, and swallowing problems. He focuses on minimally-invasive removal of growths of the voice box with the use of cutting-edge technology.
Dr. Naunheim cares for patients with complex laryngeal pathology including laryngeal cancer, laryngeal dysplasia, airway narrowing, vocal cord paralysis, vocal cord polyps, and respiratory papillomatosis. He is the medicald director of the Mass. Eye and Ear Transgender Voice center.
Dr. Naunheim’s practice also offers in-office (non-sedated, awake) procedures, such as vocal cord augmentation for paralysis, steroid and Botox injections, laser treatments of the vocal cords, and biopsies.
Dr. Naunheim is also on the forefront of research related to patient quality-of-life. He has helped implement a patient-reported outcome measure for subglottic stenosis. He has also established tradeoffs between risk of complication, likelihood of surgical success, and postoperative voice quality for laryngotracheal surgery. He uses advanced econometric methodologies to quantitatively understand patient preferences.
Clinical Interests:
- Laryngology / Voice
- Laser Treatments of the Vocal Cords
- Steroid and Botox Injections
- Vocal Cord Augmentation for Paralysis
- Voice and swallowing disorders
Treats:
- Adult
Locations
Mass Eye and Ear
243 Charles St.
Boston, MA 02114
Phone: 617-523-7900
Medical Education
- MBA, Harvard Business School*
- MD, Harvard Medical School/ BWH
- Residency, Massachusetts Eye and Ear
- Fellowship, Mount Sinai Hospital
American Board Certifications
- Otolaryngology-Head and Neck Surgery, American Board of Otolaryngology-Head and Neck Surgery
Reviews: Comments and Ratings
Patient Gateway
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
A Top Hospital in America
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.